Ellen Wei

883 citations

26 papers · 664 indexed · h-index 10

Impact in

Hematology top 5%
- Multiple Myeloma Research and Treatments
Genetics top 5%
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Hematology 14
- Multiple Myeloma Research and Treatments 9
- Chronic Myeloid Leukemia Treatments 4
Genetics 13
- Chronic Lymphocytic Leukemia Research 12

Co-authors: Suzanne Trudel (24 shared papers)A. Keith Stewart (5 shared papers)Zhihua Li (7 shared papers)Hong Chang (2 shared papers)Carla Heise (3 shared papers)Christine Chen (5 shared papers)Marion Wiesmann (2 shared papers)Donna Reece (3 shared papers)
Journals: Blood (18 papers)Molecular Cancer Therapeutics (1 paper)Clinical Cancer Research (1 paper)Journal of Clinical Oncology (1 paper)Nature Communications (1 paper)
Partner nations: Canada United States New Zealand

In The Last Decade

Ellen Wei

24 papers receiving 648 citations

Peers

Countries citing papers authored by Ellen Wei

Since Specialization

Citations

This map shows the geographic impact of Ellen Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Wei more than expected).

Fields of papers citing papers by Ellen Wei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Wei. The network helps show where Ellen Wei may publish in the future.

Co-authors

The 25 scholars most cited alongside Ellen Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ellen Wei Line = papers co-authored together Ellen Wei links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma Blood ·Suzanne Trudel, Zhihua Li, Ellen Wei, Marion Wiesmann, Hong Chang, Christine Chen, Donna Reece, Carla Heise, A. Keith Stewart	2004	223
2	Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia Journal of Clinical Oncology ·Christine I. Chen, P. Leif Bergsagel, Harminder Paul, Wei Xu, Anthea Lau, Nimisha Dave, Vishal Kukreti, Ellen Wei, Chungyee Leung-Hagesteijn, Zhihua Li, Joseph Brandwein, Mariela Pantoja, James B. Johnston, Spencer B. Gibson, Tiffany Hernandez, David Spaner, Suzanne Trudel	2010	109
3	The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells Blood ·Suzanne Trudel, A. Keith Stewart, Eran Rom, Ellen Wei, Zhihua Li, Sarit Kotzer, Irina Chumakov, Yossi Singer, Hong Chang, Sheng‐Ben Liang, Avner Yayon	2006	108
4	MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma Blood ·Esther Masih‐Khan, Suzanne Trudel, Carla Heise, Zhihua Li, Joshua Paterson, Vincent Nadeem, Ellen Wei, David Roodman, Jaime O. Claudio, P. Leif Bergsagel, A. Keith Stewart	2006	54
5	The SH3–SAM Adaptor HACS1 is Up-regulated in B Cell Activation Signaling Cascades The Journal of Experimental Medicine ·Yuan Xiao Zhu, Sally J. Benn, Zhihua Li, Ellen Wei, Esther Masih‐Khan, Young Trieu, Meenakshi Bali, C. Jane McGlade, Jaime O. Claudio, A. Keith Stewart	2004	45
6	A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL). Blood ·Christine I. Chen, Harminder Paul, Pantoja Mariela, Joseph Brandwein, Vishal Kukreti, Suzanne Trudel, Ellen Wei, Jieffei Tong, Mike Moran	2007	28
7	Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression Nature Communications ·Danielle Croucher, Laura M. Richards, Serges P. Tsofack, Daniel D. Waller, Zhihua Li, Ellen Wei, Xian Fang Huang, Marta Chesi, P. Leif Bergsagel, Michaël Sébag, Trevor J. Pugh, Suzanne Trudel	2021	20
8	Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium Blood ·Suzanne Trudel, Nizar J. Bahlis, Christopher P. Venner, Annette E. Hay, Olena Kis, Signy Chow, Zhihua Li, Ellen Wei, Lisa Wang, Christine Tran, Smitha Udagani, Chantale Blattler, Trevor J. Pugh, Helen X Chen, Amit M. Oza	2016	14
9	Murine phosphatidylserine-specific phospholipase A1 (Ps-pla1) maps to Chromosome 16 but is distinct from the lpd (lipid defect) locus Mammalian Genome ·Xiao‐Yan Wen, A. Keith Stewart, Jennifer Skaug, Ellen Wei, Lap-Chee Tsui	2001	12
10	A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) Blood ·Christine Chen, Harminder Paul, Wei Xu, Vishal Kukreti, Suzanne Trudel, Ellen Wei, Zhihua Li, Joseph Brandwein, Mariela Pantoja, Chungyee Leung-Hagensteijn	2008	9
11	Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134 Clinical Cancer Research ·Sheng-Ben Liang, Xiu-Zhi Yang, Young Trieu, Zhihua Li, Jessica Zive, Chungyee Leung-Hagesteijn, Ellen Wei, Sergey Zozulya, Christopher C. Coss, James T. Dalton, I. George Fantus, Suzanne Trudel	2011	8
12	A phase 2 study of ofatumumab (Arzerra^®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)* Leukemia & lymphoma ·Christine I. Chen, Harminder Paul, Lisa W. Le, Ellen Wei, Susi Snitzler, Trina Wang, О. А. Левина, Sumeet Kakar, Anthea Lau, Michelle L. Queau, James B. Johnston, Deborah A. Smith, Suzanne Trudel	2018	8
13	A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL) Leukemia & lymphoma ·Christine I. Chen, Harminder Paul, Susi Snitzler, Sumeet Kakar, Lisa W. Le, Ellen Wei, Anthea Lau, James B. Johnston, Spencer B. Gibson, Michelle L. Queau, David Spaner, Danielle Croucher, Barbara Sherry, Suzanne Trudel	2018	7
14	Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) Blood ·Christine Chen, Harminder Paul, Trina Wang, Lisa W. Le, Vishal Kukreti, Ellen Wei, Anthea Lau, P. Leif Bergsagel, Nimisha Dave, Suzanne Trudel	2012	4
15	GSK-3 Spatial Regulation Has an Essential Role in Lenalidomide Activity and Represents a Biomarker of Clinical Response in CLL Blood ·Suzanne Trudel, Sam Scanga, Fabrizio G. Mastronardi, Ellen Wei, Frank Mercurio, Antonia Lopez‐Girona, Svetlana Gaidarova, David R. Webb, Christine Chen, Keith Stewart, Armen S. Manoukian	2012	3
16	An Open-Label Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in the Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL). Blood ·Christine Chen, Harminder Paul, L. Rizzo, Lisa W. Le, Ellen Wei, Anthea Lau, James B. Johnston, Spencer B. Gibson, Michelle Brown, Suzanne Trudel	2012	3
17	Macrophage Inflammatory Protein (MIP)-1alpha (CCL3) Is a Downstream Target of FGFR3 and RAS Signaling in Multiple Myeloma. Blood ·Esther Masih‐Khan, Suzanne Trudel, Zhihua Li, Vincent Nadeem, Ellen Wei, Joshua Paterson, Jaime O. Claudio, A. Keith Stewart	2005	2
18	Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma Blood ·Dor Abelman, Jenna Eagles, Stephanie Pedersen, Arnavaz Danesh, Danielle Croucher, Jeffrey P. Bruce, Stephenie D. Prokopec, Ellen Wei, Saumil Shah, Alli Murugesan, Tony Reiman, Suzanne Trudel, Trevor J. Pugh	2023	1
19	CHIR258, a Novel Multi-Targeted Tyrosine Kinase Inhibitor, for the Treatment of t(4;14) Multiple Myeloma. Blood ·Suzanne Trudel, Zhihua Li, Ellen Wei, Marion Wiesmann, Katherine G. Rendahl, Eddie Moler, Christopher S. Chen, Donna Reece, Joesph Mikhael, Carla Heise, A. Keith Stewart	2004	1
20	Abstract A201: The potent STAT3/5 inhibitor, BP-1–102, demonstrates significant antitumor activity against Waldenstrom macroglobulinemia. Molecular Cancer Therapeutics ·Danielle Croucher, Víctor H. Jiménez‐Zepeda, Brent D. G. Page, Zhihua Li, Ellen Wei, James Turkson, Patrick T. Gunning, Suzanne Trudel	2011	1

About Ellen Wei

Ellen Wei is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Transplantation and Immunology, having authored 26 papers that have together received 664 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (12 papers), Multiple Myeloma Research and Treatments (9 papers), Lymphoma Diagnosis and Treatment (7 papers), Immunodeficiency and Autoimmune Disorders (5 papers), Protein Tyrosine Phosphatases (4 papers), Chronic Myeloid Leukemia Treatments (4 papers), Fibroblast Growth Factor Research (4 papers) and Protein Degradation and Inhibitors (3 papers). The work is most often cited by research in Hematology (250 citations), Genetics (176 citations), Pathology and Forensic Medicine (146 citations), Molecular Biology (425 citations) and Oncology (156 citations). Ellen Wei has collaborated with scholars based in Canada, United States and New Zealand. Frequent co-authors include Suzanne Trudel, A. Keith Stewart, Zhihua Li, Hong Chang, Carla Heise, Christine Chen, Marion Wiesmann, Donna Reece, P. Leif Bergsagel and Vishal Kukreti. Their work appears in journals such as Blood, Molecular Cancer Therapeutics, Clinical Cancer Research, Journal of Clinical Oncology and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact